Edwyn

Edwyn Search companies, tickers, CIKs…⌘K

CVS HEALTH Corp

CVSCIK 0000064803Healthcare

Compare:WBA UNH WMT CI HUM ELV

Compare CVS

Intrinsic Value

CVS Intrinsic Valuation

Review the filing-backed discounted cash flow baseline, scenario range, and capital structure context for a fundamentals-first fair value read.

Intrinsic Value

CVS Intrinsic Valuation

Review the filing-backed discounted cash flow baseline, scenario range, and capital structure context for a fundamentals-first fair value read.

Intrinsic value

Filing-backed DCF baseline

Automated free-cash-flow DCF baseline for CVS HEALTH Corp, derived from annual filing data.

Read the DCF guide

DCF fair value

$58.49

Implied equity value $74B

Current price

—

Latest available quote for the primary listing.

Margin of safety

N/A

Live market price unavailable. Refreshing the route will retry the quote.

Fair value range

$43.35 – $78.21

Bear

$43.35

Base

$58.49

Bull

$78.21

Model assumptions

Cash flow base

$9B

Basis

Operating cash flow less capex (firm-value proxy)

Growth

7.6%

Discount

10.5%

Terminal

2.5%

Horizon

Assumption sensitivity

vs base per share

Base case$58.49Baseline

Growth +1 pt$73.61+$15.12

Intrinsic value

Filing-backed DCF baseline

Automated free-cash-flow DCF baseline for CVS HEALTH Corp, derived from annual filing data.

Read the DCF guide

DCF fair value

$58.49

Implied equity value $74B

Current price

—

Latest available quote for the primary listing.

Margin of safety

N/A

Live market price unavailable. Refreshing the route will retry the quote.

Fair value range

$43.35 – $78.21

Bear

$43.35

Base

$58.49

Bull

$78.21

Model assumptions

Cash flow base

$9B

Basis

Operating cash flow less capex (firm-value proxy)

Growth

7.6%

Discount

10.5%

Terminal

2.5%

Horizon

Assumption sensitivity

vs base per share

Base case$58.49Baseline

Growth +1 pt$73.61+$15.12

What the market is pricing in

Market expectations cannot be backed out until price, share count, cash-flow base, discount rate, terminal growth, and the EV-to-equity bridge are all available.
Growth anchor: Median of 3Y revenue CAGR, 5Y revenue CAGR, and 5Y free cash flow CAGR. Scenario-derived from +/-2 pts growth and +/-1 pt discount.
Net debt reduces equity value relative to firm value before the per-share target is calculated.

Intrinsic EV-to-equity bridge

Enterprise value

Discounted free cash flows

$128B

Less total debt

− $65B

Plus cash and equivalents

+ $11B

Equity value

After the bridge

$74B

Diluted shares

1,271,000,000

Fair value / share

$58.49